GlassScriptPhysician profile
Jennifer J Gray
NPI 1649253527
$2,743.06
in general payments reported to CMS, 2019-2025
27 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $195 · 2021: $366 · 2022: $472 · 2023: $303 · 2024: $477 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $642.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $328.93 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $247.03 | 2021-2025 | |
| Novo Nordisk INC | $245.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $169.29 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Insulet Corporation | $141.79 | 2024 | Omnipod |
| Axsome Therapeutics, INC. | $94.36 | 2024-2025 | Auvelity |
| Pfizer INC. | $92.32 | 2021-2024 | |
| Amgen INC. | $84.15 | 2020-2023 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $74.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $71.87 | 2019-2022 | |
| Lilly USA, LLC | $65.65 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $49.40 | 2021 | |
| Phathom Pharmaceuticals, INC. | $44.62 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.82 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.67 | 2022 | |
| Allergan, INC. | $37.21 | 2019-2020 | |
| Hologic Sales and Service, LLC | $34.62 | 2023 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $33.44 | 2022-2023 | Trintellix |
| Sanofi Pasteur INC. | $32.25 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.85 | 2019 | |
| Astellas Pharma US INC | $27.63 | 2019-2025 | Veozah |
| Ironshore Pharmaceuticals INC. | $26.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.86 | 2023 | |
| Biogen, INC. | $25.81 | 2024 | |
| Mylan Specialty L.P. | $18.67 | 2022 | |
| Cranial Technologies, INC | $14.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.